drugset
drugset / Trial / NCT03785405

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

NCT03785405 ↗

Phase 3 Completed 216 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2 as per protocol.

Timeline

Start
2019-05-02
Primary completion
2023-12-29
Completion
2023-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject sacubitril/valsartan Unknown 3.1 mg/kg —

Indications

heart failure